Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDAmphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adultsEfficacy of Psychostimulant Drugs for Cocaine DependenceMedication for attention deficit-hyperactivity disorder and criminalityImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsOptimal management of ADHD in older adultsEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsPharmacological treatment of adult ADHD in EuropeAtomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patientsThe social and cultural construction of psychiatric knowledge: an analysis of NICE guidelines on depression and ADHD.Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?Stimulant ADHD medication and risk for substance abuse.Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.Adult attention deficit hyperactivity disorder and violence in the population of England: does comorbidity matter?Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomiseCommon ground in Attention Deficit Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD)-review of recent findingsFactors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders.Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanisms.Distinguishing comorbidity and successful management of adult ADHD.Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.Emotional dysregulation in adult ADHD: What is the empirical evidence?Is emotional dysregulation part of the psychopathology of ADHD in adults?Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.The relationship between ADHD and obesity: implications for therapy.Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults.Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD).Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009.Non-medical use of methylphenidate: a review.Attention deficit hyperactivity disorder and substance misuse: an evaluation of causal hypotheses and treatment considerations.A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.Adult ADHD: A new disease?
P2860
Q21260332-9EDBAA01-CB30-4B4A-A131-F3CD44804F8DQ24236404-7422DEB8-033B-4DEE-B29A-2510F2682464Q24239994-CEFF2D73-955E-4711-A7AC-5F2A23E75408Q24619697-79FBF13B-DE07-45A1-94B2-8FE6786CE8FDQ26471999-055B5080-B365-4383-AF9F-72CA6A08F1FBQ26774425-0FDE1D6B-C65A-483F-8F42-A6C0312248A3Q28246506-8E92F770-BED2-4EFA-B039-6E5699A19E39Q28247634-CEE2A95B-CAA2-4A3A-9BE3-1960056F3356Q28267079-F0F61A46-98E9-4C3B-B0A8-24EED2B080B9Q30428292-1487C915-528C-482F-A68E-53A49AD64F28Q33919950-7C3CDDC1-FC9F-492D-B95E-A9CB0EC4AAD6Q34102167-80C00405-B4D6-4A7F-976F-4FCDCE6DCD39Q34394522-949B34E6-4FB4-4E6D-9A20-FFD67A3E8347Q34475309-B10FAA77-B695-4AA6-883B-BE3A3C62C87DQ34497314-8A522353-C27A-4417-BC3C-A1EE54EA2704Q34505285-FD75DBEE-24FD-4F1E-874B-1960E66E8BFDQ35005776-957306A4-AEF3-44B1-AEE1-05E6BB3BF125Q35755924-A797D362-055A-422A-BB9A-A29AC9967AB6Q36364178-582505EA-BDE0-4A63-8783-282EA92DFF4CQ36538675-7AF19E97-73F9-41BA-9015-F6204BE468E0Q36813731-ACB8921C-D17B-4A2E-8474-89026D06759DQ37598192-CD40B8CB-A056-43A4-8044-9A4EE3BA0763Q37827879-BE3278AE-0A04-418D-8639-6E24791EEFE0Q37940001-B3EEC7B8-EFC6-4E58-96FD-CFAC50F68F24Q38002290-3B3F898A-4D49-4A7A-ADB3-595A050566EDQ38043921-A1E47BFF-F5CC-444C-AF6C-F6D93ED6B191Q38053447-535367AA-CBCC-4389-A813-DD900360A261Q38064762-D11F3723-E508-4B2B-B8FD-71E38F376E4BQ38065287-5DC2787C-B7B7-445E-9E44-D3067506A925Q38187892-4E957C21-4F49-407F-B73F-4445B75F1B20Q38202135-DC7296A1-791B-4FE1-8DE8-6E249319C319Q38205020-1F35B14D-7F91-4D04-9DCF-5A95F7353C12Q38241724-2FF1E15B-7277-4477-9C82-4408B2DC3F0FQ38243174-D6A02BD5-ED9C-4D53-876A-AF58DC30F341Q38251282-CDB91945-E8DA-45C0-B7A3-ABF289BD53BDQ38430606-DDF11408-C5FA-4ACF-9781-A0B1AD30DD39Q38448645-E090498A-2657-40CB-8450-1995EC067871Q38569727-D4D10A6F-78F1-41EF-B3F0-E768F408E515Q38785464-57F83394-A62F-4E98-8388-4D8FF1A4DAF7Q38799949-8FE3B80E-639E-40C0-AB75-41D3F623BB82
P2860
Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@en
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@nl
type
label
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@en
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@nl
prefLabel
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@en
Limits of meta-analysis: methy ...... eficit hyperactivity disorder.
@nl
P2093
P2860
P921
P356
P1476
Limits of meta-analysis: methy ...... deficit hyperactivity disorder
@en
P2093
P2860
P304
P356
10.1177/0269881108092338
P407
P577
2008-06-18T00:00:00Z